Clinical Scorecard: Factors Influencing Axillary Pathological Complete Response in Patients with HER2-Positive Breast Cancer Undergoing Neoadjuvant Chemotherapy

At a Glance

Key Highlights

• Neoadjuvant chemotherapy plus anti-HER2 therapy achieves axillary pCR in up to 74% of HER2+ breast cancer cases.
• Sentinel lymph node biopsy (SLNB) and targeted axillary dissection (TAD) are effective less invasive alternatives to axillary lymph node dissection (ALND) in selected patients.
• Axillary radiologic complete response (rCR) assessed by ultrasound and MRI post-NAC is a key predictor for safely omitting ALND.

Guideline-Based Recommendations

Diagnosis

• Use pre- and post-NAC imaging including mammography/tomosynthesis, breast and axillary ultrasound, and breast MRI for staging and response assessment.
• Define suspicious lymph nodes by ultrasound morphology (Bedi’s classification types 4-6).
• Assess breast rCR by absence of contrast enhancement on dynamic contrast-enhanced MRI.

Management

• Perform SLNB or TAD instead of ALND in patients achieving axillary pCR after NAC, especially with ≤3 suspicious nodes at diagnosis.
• Consider expanding ALND criteria to ≥4 suspicious nodes in HER2+ patients due to high axillary pCR rates.
• Administer NAC combined with anti-HER2 agents as standard for HER2+ breast cancer with axillary involvement.

Monitoring & Follow-up

• Evaluate axillary response post-NAC primarily by ultrasound normalization of lymph node morphology (cortical thickness <3 mm, restored hilum).
• Use MRI and ultrasound to monitor tumor size and lymph node changes before and after NAC.

Risks

• ALND is associated with significant morbidity including lymphedema, chronic pain, and reduced arm mobility.
• Incomplete assessment or inaccurate imaging interpretation may lead to under-treatment or overtreatment of axillary disease.

Patient & Prescribing Data

HER2+ breast cancer patients with biopsy-confirmed axillary involvement undergoing NAC

NAC combined with anti-HER2 therapy significantly increases axillary pCR rates, allowing for less invasive surgical approaches and reducing lymphadenectomy-related complications.

Clinical Best Practices

• Multidisciplinary decision-making for NAC administration and surgical planning.
• Standardized imaging protocols pre- and post-NAC including mammography/tomosynthesis, ultrasound, and MRI.
• Use of ultrasound-based axillary rCR criteria to guide surgical management decisions.
• Consider patient-specific factors such as initial nodal burden and radiologic response when selecting axillary surgery approach.

References

• National Surgical Adjuvant Breast and Bowel Project B-32 Trial
• ACOSOG Z0011 Trial
• ACOSOG Z1071 Study
• García-Tejedor Study on SLNB after NAC
• Bedi’s Ultrasound Classification of Lymph Nodes